$0.38 EPS Expected for Natus Medical Inc (BABY)

September 17, 2017 - By Winifred Garcia

 $0.38 EPS Expected for Natus Medical Inc (BABY)
Investors sentiment increased to 1.93 in 2016 Q4. Its up 0.82, from 1.11 in 2016Q3. It is positive, as 11 investors sold Natus Medical Inc shares while 56 reduced holdings. 51 funds opened positions while 78 raised stakes. 29.10 million shares or 6.34% more from 27.36 million shares in 2016Q3 were reported.
Kennedy Capital Mgmt has 0.17% invested in Natus Medical Inc (NASDAQ:BABY) for 280,102 shares. Moreover, First Mercantile Trust has 0.06% invested in Natus Medical Inc (NASDAQ:BABY) for 11,741 shares. Fincl Advisers Limited Co stated it has 0% of its portfolio in Natus Medical Inc (NASDAQ:BABY). Prelude Management Lc reported 4,275 shares stake. Farmers And Merchants Invs owns 0% invested in Natus Medical Inc (NASDAQ:BABY) for 187 shares. Blackrock Gru Limited holds 64,588 shares or 0% of its portfolio. Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Mngmt, a Alberta – Canada-based fund reported 7,000 shares. 215,133 were accumulated by Jpmorgan Chase. Rhumbline Advisers accumulated 48,317 shares. Point72 Asset Mgmt Lp reported 74,900 shares. Balyasny Asset Mgmt Limited Liability Com invested in 6,100 shares or 0% of the stock. Paloma Prns owns 21,685 shares. Virginia Retirement Sys Et Al has invested 0.01% in Natus Medical Inc (NASDAQ:BABY). State Of Alaska Department Of Revenue invested in 3,570 shares or 0.01% of the stock. Strs Ohio owns 25,300 shares for 0% of their portfolio.

Since May 25, 2017, it had 2 buys, and 1 sale for $175,360 activity. 5,000 shares were sold by Engibous Doris, worth $163,400 on Thursday, May 25.

Investors wait Natus Medical Inc (NASDAQ:BABY) to report on October, 18. its quarterly earnings Wall Street analysts expect $0.38 earnings per share, down $0.01 or 2.56 % from last year’s $0.39 same quarter earnings. This translates into $12.56 million profit for BABY giving the stock a 23.09 P/E. This is assuming the current $0.38 EPS is accurate. Natus Medical Inc’s Wall Street analysts see 11.76 % EPS growth, taking into account the $0.34 EPS reproted in the previous quarter, The stock decreased 1.40% or $0.5 on September 15, reaching $35.1. About 310,860 shares traded. Natus Medical Inc (NASDAQ:BABY) has risen 4.38% since September 17, 2016 and is uptrending. It has underperformed by 12.32% the S&P500.

Natus Medical Inc (NASDAQ:BABY) Ratings Coverage

Among 4 analysts covering Natus Medical (NASDAQ:BABY), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Natus Medical had 9 analyst reports since July 23, 2015 according to SRatingsIntel. Roth Capital maintained the stock with “Buy” rating in Tuesday, April 5 report. The firm has “Buy” rating given on Monday, September 11 by Roth Capital. The stock of Natus Medical Inc (NASDAQ:BABY) has “Buy” rating given on Friday, June 23 by Roth Capital. The firm earned “Buy” rating on Tuesday, January 12 by TH Capital. The stock of Natus Medical Inc (NASDAQ:BABY) has “Buy” rating given on Thursday, October 22 by TH Capital. TH Capital maintained Natus Medical Inc (NASDAQ:BABY) rating on Thursday, July 23. TH Capital has “Buy” rating and $51 target. The stock of Natus Medical Inc (NASDAQ:BABY) has “Mkt Perform” rating given on Thursday, February 2 by Raymond James. As per Tuesday, October 4, the company rating was initiated by Benchmark. The rating was upgraded by Raymond James on Tuesday, September 13 to “Outperform”.

Natus Medical Incorporated is a provider of newborn care and neurology healthcare services and products used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders. The company has market cap of $1.16 billion. The Company’s product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products, such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn’s environment, and software systems for managing and tracking disorders and diseases for public health laboratories. It has a 61.62 P/E ratio.

More notable recent Natus Medical Inc (NASDAQ:BABY) news were published by: Fool.com which released: “Why Natus Medical Inc. Sank Today” on April 26, 2017, also Fool.com with their article: “Natus Medical Inc. Fell 11% in April. Here’s Why.” published on May 08, 2017, Nasdaq.com published: “Natus Medical Inc (BABY) President and CEO James B Hawkins Bought $135920 of …” on June 16, 2017. More interesting news about Natus Medical Inc (NASDAQ:BABY) were released by: Fool.com and their article: “Natus Medical Incorporated in 4 Charts” published on December 05, 2016 as well as Nasdaq.com‘s news article titled: “Eos Focused Equity Management, LP Buys Univar Inc, Natus Medical Inc, General …” with publication date: August 08, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.